Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | Journal article |
语言: | English |
出版: |
Elsevier
2019
|